Healthcare
15 healthcare startups based in La Jolla, $455.3M raised total, led by Inhibrx, Inc. ($200.0M raised). See what Healthcare means more broadly on the Healthcare industry page.
The breakdown
14 of 15 companies have disclosed funding, $455.3M combined, 4 at Series A stage, making up 56% of the 27 La Jolla startups on file across every industry, founding dates span 2019-2024.
Companies
$200.0MAnchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.
Series A$99.0MEnlaza Therapeutics is pioneering the field of covalent biologics, developing a novel classes of protein therapeutics based on its proprietary War-Lock™ platform.
Series B$27.1MAlume Biosciences is developing nerve illumination technology, specifically bevonescein (ALM-488), to help surgeons protect and preserve nerve function during surgery by making nerves glow.
Series B$20.3MSYLKE® Skin Closure is a sterile, single-use, silk fibroin mesh strip with a pressure-sensitive adhesive intended for topical skin closure and wound support. The device is used to hold together well-approximated skin edges of a wound, and to cover and protect the wound. Learn more at sylke.com.
Seed$18.6MSpinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
Series B$18.5MPaulex Bio stands at the threshold of what could be a transformative breakthrough for type 1 and type 2 diabetes: beta cell regeneration through an oral medicine designed to eliminate the root cause of diabetes.
Series A$15.7MModel Medicines engineers first-in-class small molecules against biological choke points, using AI to advance pipeline-in-a-pill therapeutics across high-impact diseases.
Seed$14.8MWe explore the immense therapeutic opportunities to help those bound by autoimmune neuropsychiatric diseases.
Seed$13.0MValora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.
Series A$10.4MAeroRx Therapeutics is developing potential best-in-class nebulized combination therapies to improve COPD treatment.
$10.0MLearn how Genomic Life enhances health and well-being through genetic screenings, early detection, personalized cancer navigation, and ongoing support. Optimize employee benefits and create a healthier workforce.
Seed$950KImpulse Medical Technologies - A leading manufacturer and distributor of high-quality medical electrodes and diagnostic supplies. Parent company of The Electrode Store and TES Wholesale.
Sarmal is developing proprietary single molecule DNA sequencing technology and target detection technology for genomic detection.